Rubius Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Rubius Therapeutics

08/11/2021 23:35

* Rubius Therapeutics Inc  RUBY.OQ  reported a quarterly
adjusted loss of 55 cents​​ per share for the quarter ended in
September. The mean expectation of six analysts for the quarter
was for a loss of 57 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Rubius Therapeutics Inc's reported EPS for the quarter was a
loss of 55 cents​.
* The mean earnings estimate of analysts had fallen by
about 8.2% in the last three months.​ 
* In the last 30 days one analyst negatively revised an earnings
estimate 
* Rubius Therapeutics Inc shares had fallen by 17.4% this
quarter and gained 94.5% so far this year.
* The company reported a quarterly loss of $49.02 million.
* Wall Street's median 12-month price target for Rubius
Therapeutics Inc is $32.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 8 at 11:35 p.m.
 ​All figures in US dollars unless otherwise stated